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Disorders of diminished motivation
A B S T R A C T
Akinetic mutism (AM) is a rare neurological disorder characterized by the presence of an intact level of con-
sciousness and sensorimotor capacity, but with a simultaneous decrease in goal-directed behavior and emotions.
Patients are in a wakeful state of profound apathy, seemingly indifferent to pain, thirst, or hunger. It represents
the far end within the spectrum of disorders of diminished motivation. In recent years, more has become known
about the functional roles of neurocircuits and neurotransmitters associated with human motivational behavior.
More specific, there is an increasing body of behavioral evidence that links specific damage of functional frontal-
subcortical organization to the occurrence of distinct neurological deficits. In this review, we combine evidence
from lesion studies and neurophysiological evidence in animals, imaging studies in humans, and clinical in-
vestigations in patients with AM to form an integrative theory of its pathophysiology. Moreover, the specific
pharmacological interventions that have been used to treat AM and their rationales are reviewed, providing a
comprehensive overview for use in clinical practice.
1. Introduction
Akinetic mutism (AM) is a rare neurological disorder of impaired
initiation and motivation for behavior. Patients with AM maintain an
intact level of consciousness, attention, language, and sensorimotor
capacity, but present with a simultaneous decrease in goal-directed
behavior, and emotion.(Miller and Cummings, 2018) Since its initial
description in 1941, AM has been associated with structural damage to
a considerable variety of functional brain areas. The disorder has been
described in patients with cerebrovascular disease, with obstructive
hydrocephalus, with tumors in the region of the third ventricle, and in
patients suffering from other conditions affecting structural compo-
nents of frontal-subcortical circuits. As a result of the wide variety of
these lesions, AM has previously been described as a 'syndrome with
little localizing value'.(Skultety, 1968) Moreover, the disease is
associated with a characteristic clinical heterogeneity that makes it
difficult to diagnose. However, in recent years significant advances
have been made in the understanding of the neuroanatomy, neuro-
physiology, and chemoarchitecture of neurocircuits that are involved in
the initiation and motivation of behavior. In parallel with these de-
velopments, an increasingly broad spectrum of neurologic and neu-
ropsychiatric phenomenology is being recognized as interpretable in
the context of dysfunction of motivational circuitry.(Miller and
Cummings, 2018) In addition, clear criteria for the assessment of pa-
tients with altered states of consciousness have been established, fa-
cilitating the distinction between conative disorders and, for example,
the minimally conscious state.(Aspen Workgroup, 1995) These ad-
vances provide the opportunity to formulate an integrative theory of
the development of AM in the context of dysfunction of specific frontal-
subcortical neurocircuits. In this review, we combine evidence from
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recent animal and human studies in order to define the clinical con-
sequences of frontal-subcortical disconnection and do an attempt to
clarify the pathophysiology of AM. Subsequently, we review treatment
strategies for patients with AM, and their rationale, with the aim to
provide a comprehensive overview for use in clinical practice.
2. Definition of akinetic mutism
In search for the use of uniform nomenclature for disorders of al-
tered consciousness, the American Congress of Rehabilitation Medicine
(Aspen workgroup) has formulated specific neurobehavioral criteria for
AM. In general, patients with AM show a lack of voluntary movement
(akinesia) and absence of speech (mutism), though eye opening and
spontaneous or environmentally induced visual tracking remain well
maintained. Patients seem awake, but do not display affective reactions,
do not initiate eating or drinking, and if speech occurs, it remains
sparse. There is a great variety in associated neurological symptoms.
(Giacino et al., 2014) While some patients show a minimal degree of
command following and verbalization, others remain largely apathetic
and akinetic. In the spectrum for disorders of diminished motivation,
AM seems to represent an extreme form of abulia (absence of will-
power). AM has been described in both children as adults of both sexes,
and, in general, has no correlations with previous medical or psychia-
tric conditions.(Cairns et al., 1941) However, it may resemble other
hyporesponsive conditions with a different underlying pathophy-
siology. The heterogeneity among patients with AM raises the possibi-
lity of misdiagnosing the condition with other diseases, such as psy-
chiatric disorders, including catatonic schizophrenia, severe depression,
conversion reaction, or other structural disorders, such as locked-in
syndrome.(Fisher, 1989; Giacino, 1997; Nagaratnam et al., 2004;
Shetty et al., 2009) As a result of this heterogeneity, the term AM has
sometimes been used too extensively and improperly in the literature.
(Kemper and Romanul, 1967; Nemeth et al., 1988) In general, patients
with AM show variations of the same basic disorder: a state of dimin-
ished motor function, compromised speech, movement and facial ex-
pression, but with preservation of sensory functions and awareness.
(Giacino et al., 2014)
While AM is associated with a failure to initiate spontaneous, vo-
luntary responses, patients maintain the intrinsic capacity to move or
speak.(Tibbetts, 2001) It might be a permanent condition after irre-
versible brain injury, though also be of temporary origin, if neurological
recovery occurs, suggesting a considerable preservation of both speech
and motor functions. The preservation of executive functions is also
strikingly demonstrated in AM patients that experience a supposedly
‘telephone effect’, referring to unpredictable events, such as a ringing
telephone or other verbal or environmental stimuli that cause a sudden
restoration of speech and movement, possibly by a brain functioning on
some sort of ‘automatic pilot’.(Fisher, 1983; Yarns and Quinn, 2013)
These patients quickly loose these capacities when the stimulus ends.
The severity of the akinesia and mutism usually impairs any relational
exchange with others, and renders patients wheelchair-bound, and
completely depended of nursing care. Furthermore, the akinesia and
mutism usually complicate daily care and prevent the deployment of
any rehabilitation interventions. Although AM patients are conscious,
they appear to lack the vector to express pain or any inner feelings, if
present, to the outside world, which is often devastating for their fa-
milies. Up until today, little is known about the emotional and psy-
chological state of AM. Previously, one patient with AM responded to
the question of why she did not talk during her illness with the answer
‘nothing ever came to mind’, suggesting a complete absence of thinking
or reasoning.(Damasio, 1994) It goes without saying that it remains
important that the diagnosis of AM should be made only after careful
judgment of accompanying signs and in the whole context of the clin-
ical presentation.(Tibbetts, 2001) For instance, it must be distinguished
from anarthria and apraxia of speech, conditions wherein there is an
inability to speak, but in which attempts to communicate by gesture or
facial expression are often successful. Accompanying cognitive im-
pairments, that are often inherent to the underlying brain injury, are
usually clinically assessed by a subset of cognitive screening tests, such
as the Mini Mental State Examination (MMSE) and the Montreal Cog-
nitive Assessment test (MOCA), though the value of these neurobeha-
vioral assessment tools is often limited, because of the inability of pa-
tients to speak or move.
3. Pathophysiology of akinetic mutism
Distinct neurocircuits have been described that provide the neural
basis of motivation.(Kalivas and Barnes, 2019) A wide variety of mo-
tivational deficits might develop after damage to frontal-subcortical
structures that are involved in the translation of a motivational stimulus
in a behavioral response. Along the way of the frontal-subcortical
system, specific structures are found that are associated with the de-
velopment of AM:
3.1. The role of the anterior cingulate cortex (ACC) and striatum
3.1.1. The ACC
The frontal lobes act as integrator of information, processing both
input from the external sensory world and internal limbic system.
(Miller and Cummings, 2018) This function is reflected in the organi-
zation, physiology, and connections between areas of the frontal cortex
and their afferent and efferent projections with the subcortical system.
(Haber, 2016) The frontal cortex can be divided into several general
functional regions: the orbital and medial prefrontal cortex (PFC), in-
volved in emotions and motivation; the dorsolateral PFC, involved in
higher cognitive processes or executive functions; the premotor areas,
involved in different aspects of motor planning; and the motor cortex,
involved in the execution of those plans. The development of symptoms
of diminished motivation, lethargy, and a general loss of interest is
closely related to lesions of different regions of the frontal cortex.
However, there is converging evidence that the medial walls of the
frontal lobes, particularly the anterior cingulate cortex (ACC), form a
‘usual suspect’ in the development of AM.(Darby et al., 2018; Devinsky
et al., 1995; Tibbetts, 2001) The ACC has complex reciprocal connec-
tions with limbic structures and other parts of the frontal cortex and is
thought to provide an interface between the decision-making process of
the frontal lobe and the ‘emotional’ world of the limbic system. The
ACC is responsible for learning and selecting high-level behavioral
plans that provide the meaning behind and motivation for actions, and
is thought to be essential in making a transition from early premotor
processes to actual behavior.(Holroyd and Yeung, 2012) Moreover, it is
thought to be crucial in the voluntary initiation of speech and vocali-
zation through connections with brainstem periaqueductal grey that in
turn connects with brainstem nuclei that innervate the muscles of ar-
ticulation and phonation.(Jurgens, 2009; Medford and Critchley, 2010;
Shenhav et al., 2013) Damage to the ACC is known to be a primary
cause for akinesia and mutism and has frequently been described in
case-reports of patients with bleeding, stroke, or other types of severe
brain injury.(Choudhari, 2004; Nemeth et al., 1988) The most dramatic
examples of akinesia and mutism follow bilateral lesions of the ACC,
such as after bilateral damage to the vascular supply of the anterior
cerebral artery territory.(Choudhari, 2004; Freemon, 1971;
Nagaratnam et al., 2004; Nemeth et al., 1988) Unilateral ACC lesions
have also been described as a cause of AM, though these usually only
produce a transient phase of motivational dysfunction followed by
gradual recovery.(Damasio and Anderson, 1993; Tibbetts, 2001) In a
recent study, Darby et al., used a new lesion network mapping tech-
nique in MR-images of patients with AM and abulia and were able to
show that patients with AM all experienced impairment of one specific
network defined by connectivity to the ACC.(Darby et al., 2018)
However, extensive damage to the ACC has also been reported without
the occurrence of disorders of diminished motivation. For example,
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patients failed to develop AM after therapeutic bilateral anterior cin-
gulotomies.(Ballantine et al., 1967; Livingston, 1953) Moreover, many
patients with aneurysms of the anterior communication artery have
undergone surgical ligation of both anterior cerebral arteries at the
genu of the corpus callosum, which usually causes a stroke in the
anterior cingulate gyrus, without suffering from AM.(Freemon, 1971;
Meyers, 1951) Therefore, it remains uncertain whether ACC dysfunc-
tion alone is sufficient to result in a state of extreme sensory inattention
and reduced behavioral output. It is known that the ACC is tightly
linked with many other PFC areas, including most areas of the dorsal
PFC, associated with cognitive control, and more posteriorly with
motor control areas.(Haber, 2016) Most of the dramatic behavioral
changes following ACC lesions are therefore thought to be associated
with additional lesions, or impaired network functioning, in these ad-
jacent areas of the frontal cortex.(Meador et al., 1986; Nemeth et al.,
1988) Simultaneous impairment of both ACC and its connections with
the supplementary motor area is known to produce more pronounced
symptoms of akinesia and mutism, or even a qualitatively different state
than those caused by ACC lesions alone.(Meador et al., 1986; Nemeth
et al., 1988).
3.1.2. The striatum
Input from the frontal lobes terminates in the striatum (Fig. 1). The
striatum comprises the caudate nucleus and putamen (dorsal striatum,
DS) and nucleus accumbens (ventral striatum, VS). Connections from
the frontal cortex are generally topographically organized in the
striatum. Prefrontal areas project primarily to the VS, rostral caudate
nucleus and putamen, while sensorimotor areas project more caudally,
primarily to the putamen. While these distributions seem to form par-
allel and segregated cortico-basal ganglia circuits, there is extensive
convergence of inputs from different functional regions in the brain.
(Groenewegen et al., 2017; Haber, 2016) Overlap between the projec-
tions from the different (pre)frontal cortical areas with parietal, occi-
pital, and temporal areas at the level of the striatum provides the
anatomical substrate for interactions and integration of information
between circuits that shape behavior. Of particular interest are the
projections from the ACC to the ventromedial part of the striatum, in-
cluding the shell region of the nucleus accumbens, which are particu-
larly involved in ‘cognitive coloring’ of motivation.(Choi et al., 2017;
Duffy, 2000; Heilbronner et al., 2016; Kalivas and Barnes, 2019) The
latter part can be considered as a transition zone between the striatum
and limbic structures, like the bed nucleus of the stria terminalis.
(Groenewegen et al., 2016; Haber and McFarland, 1999) Neurons in the
nucleus accumbens shell not only project to ‘classical’ striatal targets
like the pallidum and the substantia nigra, but also to preoptic and
lateral hypothalamic areas and to mesencephalic areas beyond the
substantia nigra.(Haber et al., 1990) In this way, the ACC not only has
direct subcortical projections to the periaqueductal grey (see above),
but may also indirectly, i.e., via the ventromedial striatum, influence
subcortical structures like the lateral hypothalamus and the mesence-
phalic tegmentum.(Kalivas and Barnes, 2019)
Not surprisingly, the striatum has been implicated in several neu-
rological disorders that are characterized by dysfunction of motiva-
tional processes, such apathy, depression, and AM. For instance, sym-
metrical bilateral destruction of the striatum is known to produce a
picture of cognitive deterioration with absence of voluntary move-
ments.(Hawke and Donohue, 1951) Damage to the ventromedial
striatum is known to produce anhedonia (loss of interest), as it is closely
linked to reward valuation, decision-making, anticipation and motiva-
tion.(Der-Avakian and Markou, 2012; Kalivas and Barnes, 2019)
However, disorders of diminished motivation are more frequently as-
sociated with damage to the DS, in particular the caudate nucleus,
which is a key structure involved in planning of actions and executive
functions.(Levy and Dubois, 2006; Monchi et al., 2006) In a review of
patients with focal lesions of the basal ganglia, abulia occurred with 18
of 64 (28 %) small and large caudate lesions, 15 of which were uni-
lateral.(Bhatia and Marsden, 1994) Moreover, unilateral or bilateral
lesions of the dorsal portion of the head of the caudate nucleus are
associated with a severe form of apathy: athymhormia.(Habib, 2004;
Habib and Poncet, 1988) In both human and experimental animals,
bilateral lesions, which include the head of the caudate nucleus, have
also been associated with behavioral changes similar to AM.(Freemon,
1971; Mendez et al., 1989) In a more recent case-report, Jang et al. used
diffusion tensor tractography in a patient with slowly progressive de-
toriation from abulia to AM after traumatic brain injury and showed
remarkable damage to the prefrontal-caudate tract.(Jang et al., 2017)
They hypothesized that degeneration of these circuits is responsible for
the aggravation of abulia to AM with time. Paradoxically, other authors
reported no evidence of disorders of diminished motivation after ex-
tensive bilateral damage to the caudate nucleus, so its role in the
Fig. 1. Schematic overview of frontal-subcortical circuitry
associated with motivation and possible site(s) of action of
pharmacological interventions in AM. Purple arrows represent
the direct pathway, blue arrows represent the indirect
pathway, and green arrows represent dopaminergic pathways.
AT = Atomoxetine; BC = Bromocriptine; DS/VS = dorsal
striatum/ventral striatum; GPe/vp = globus pallidus ex-
ternus/ventral pallidum; GPi/vp = globus pallidus internus/
ventral pallidum; LD = Levodopa; MP = Methylphenidate;
SNc/vta = substantia nigra pars compacta/ventral tegmental
area; stn = subthalamic nucleus; ZPD = Zolpidem.
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development of AM remains uncertain.(Freemon, 1971; Meyers, 1942)
3.2. The role of mesolimbic and nigrostriatal dopaminergic pathways
The dopaminergic neurons, located in the ventral tegmental area
(VTA) and substantia nigra pars compacta (SNc) in the midbrain play
an important role in motivational neurocircuitry and modulate a broad
range of behavioral and motor control processes.(Haber, 2014, 2016)
Not surprisingly, damage to the dopaminergic neurons at their site of
origin is a well-known cause of AM and the disease has frequently been
reported after mesencephalic damage, such as in the case of stroke.
(Alexander, 2001; Kim and You, 2017; Nemeth et al., 1986) From the
midbrain, the VTA projects to the nucleus accumbens of the VS and
prefrontal cortex via the mesocortical limbic system. The neurons of the
SNc, in turn, project to the caudate and putamen of the DS through the
nigrostriatal pathway.(Haber, 2014) Pharmacological and dopamine
(DA) depletion studies demonstrate a critical role for mesolimbic DA in
motivational behavior.(Salamone and Correa, 2012) While the role for
nigrostriatal DA appears less dominant, both mesolimbic and nigros-
triatal DA activity seems to be able to both gate input of sensory, motor,
and incentive motivation-related signals to the striatum.(Horvitz, 2002)
Therefore, both pathways are important ‘usual suspects’ in the devel-
opment of AM. It is widely known that lesions of these pathways that
convey DA from the midbrain to specific regions of the forebrain are
associated with the occurrence of behavioral deficits.(Beaulieu and
Gainetdinov, 2011) In the very first report of AM, Cairns et al., already
associated the occurrence of AM to damage of fiber pathways alongside
the third ventricle.(Cairns et al., 1941) In 1981, Ross and Stewart
specified these pathways to be dopaminergic projections from midbrain
to forebrain and described AM in a patient with disruption of these
projections as result of a large hypothalamic tumor.(Ross and Stewart,
1981) Lesion studies in animals further confirm the critical role of
mesolimbic and nigrostriatal DA pathways in behavior. For instance,
bilateral or unilateral blocking injections in the substantia nigra, VTA,
or nigro-striatal tract within the medial forebrain bundle have been
shown to cause dramatic behavioral deficits.(Ungerstedt, 1970, 1971)
Damage to any of these structures seem to result in a change in feeding,
drinking, motor behavior, and in sensory and orienting functions in
animals that seem equivalent to symptoms of AM in humans. These
behavioral deficits could be reversed by administration of apomor-
phine, a direct dopamine agonist, and blocked by pre-treatment with
spiroperidol, a dopamine receptor antagonist.(Ljungberg and
Ungerstedt, 1976; Marshall and Gotthelf, 1979; Marshall and
Ungerstedt, 1976) AM can also arise following indirect disruption of
dopamine pathways, such as in hydrocephalus.(Messert et al., 1966;
Rebai et al., 2012) Reduction of ventricular dilatation by ventricular
drainage or lumbar puncture of cerebrospinal fluid is known to produce
regression of symptoms, possibly by restoring the dopaminergic input
from the midbrain projections.(Messert et al., 1966) This finding was
further investigated in experimental hydrocephalus models in rabbits
that showed reductions in DA release in different brain structures after
ventricular dilatation, particularly in the striatum, SNc, and medial
portion of the nigrostriatal pathway.(Kondziella et al., 2008; Tashiro
et al., 1997)
3.3. The role of the basal-ganglia, thalamus, and their cortical projections
3.3.1. The pallidal complex
The pallidal complex includes the internal (GPi) and external seg-
ments (GPe) of the globus pallidus and ventral pallidum (VP). The GPi
and GPe receive inputs from both the caudate nucleus and putamen
(DS). The VP is a mixture of GPi and GPe elements and receives its input
from the VS.(Haber, 2016) The outputs from the GPi are to the tha-
lamus, which then projects back to the cortex, forming part of the ‘di-
rect’ cortico-basal ganglia circuit (Fig. 1). The GPe and parts of the VP
project to the subthalamic nucleus (STN). The STN, in turn, provides
inputs to the GPi. This pathway is considered the ‘indirect’ pathway.
The STN also receives direct projections from different parts of the
frontal cortex, which are referred to as the hyperdirect pathway. As a
result of the high convergence from the striatum to the GPi, one GPi
neuron receives input from many striatal projection neurons. There is
considerable, converging evidence to consider the (ventral) striato-
pallidum as an interface between motivation and action, or as the site of
conversion of motivational processes into behavioral output.(Habib,
2004) Not surprisingly, pallidal damage has been associated with the
occurrence of a wide variety of motivational disorders, such as AM.
(Habib, 2004) In 1989, Laplane et al., already described a lack of in-
itiative, mental slowing, and obsessive-compulsive behavior in a
number of cases that had sustained bilateral GP lesions and showed
signs of frontal hypometabolism on PET-CT’s.(Laplane et al., 1989)
Further imaging studies showed that bilateral lesions of the GP were
associated with reduced blood flow in multiple frontal cortical regions,
most prominently in the anterior parts of the frontal cortex, anterior
cingulate and supplementary motor cortex.(Haaxma et al., 1993) A
remarkable number of AM patients have been described after con-
siderable, both unilateral and bilateral anatomical destruction of the
GP.(Strub, 1989; Ure et al., 1998) Noticeably, a significant proportion
of these reports have been related to GP damage after carbon monoxide
(CO) poisoning.(Cravioto et al., 1960; Mackintosh, 1965; Tengvar et al.,
2004; Ure et al., 1998) These patients usually develop the disease after
a lucid interval from days to weeks, but typically within approximately
one month. Neuroimaging findings in these patients have shown that
CO intoxication is characterized by necrosis, particularly at the level of
the GP, possibly by the hypotensive effects of CO intoxication in the
watershed territory of the arterial supply of the GP, or as a result of CO
binding to its intrinsic high iron concentration.(Lo et al., 2007) While
the caudate nucleus, putamen, and thalamus are occasionally affected
in CO poisoning, they are involved to a much lesser extent than the GP.
Specific neuroimaging studies have repeatedly demonstrated significant
hypoperfusion in frontal regions and anterior cingulate cortices in pa-
tients with CO poisoning and GPi lesions. However, while the GP seems
to play a distinctive role in behavioral mechanisms, bilateral pallido-
tomies performed for the treatment of movement disorders did not
produce AM.(De Bie et al., 2002) The complex role of the different (sub)
portions of the GP in motivation for behavior remains subject of on-
going research in animals and humans.(Saga et al., 2017)
3.3.2. The thalamus
The thalamus is a critical component of frontal-subcortical circuitry.
Each functional region of the frontal cortex is innervated by specific
areas of the thalamus. Due to its central position in the frontal-sub-
cortical system, the thalamus has an important role in the synchroni-
zation of motivation and behavior, because it integrates information
between different functional regions.(Haber and Calzavara, 2009) Af-
ferent projections from the frontal regions project through the basal
ganglia to distinctive regions of the ventral anterior (VA), midline/in-
tralaminar and mediodorsal thalamus, which are known to be involved
in goal-directed behavior.(Tekin and Cummings, 2002) Different parts
of the thalamus then project back to different regions of the cortex and
basal ganglia. For instance, the intralaminar nuclei, including the cen-
tromedian, parafascicular nuclei, central medial, paracentral, and cen-
tral lateral nuclei project to the orbitofrontal and mediofrontal cortex,
motor and premotor cortex, and GPi, while the mediodorsal nucleus
projects to the prefrontal cortex and VP.(Van der Werf et al., 2002) In
addition, the thalamus sends a massive, topographically organized
projection directly back to the striatum. A variety of behavioral changes
and deficits, such as apathy, disinhibition syndromes, and personality
changes have been described after damage to specific regions of the
thalamus. AM has particularly been described after paramedian terri-
tory infarction.(Castaigne et al., 1981; Segarra, 1970; van Domburg
et al., 1996) Infarcts in the paramedian territory mainly involve the
mediodorsal and intralaminar nuclei.(Carrera and Bogousslavsky,
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2006) The classic features of acute paramedian infarcts include a de-
creased level of consciousness, vertical gaze paresis, and cognitive im-
pairment. However, akinesia, mutism, and reduced spontaneous ac-
tivity become apparent when the decreased level of consciousness
resolves. Moreover, other behavioral deficits may develop after tha-
lamic stroke, such as personality changes with disinhibited behavior,
apathy, loss of self-activation, and amnesia, depending on slight ana-
tomical variations in thalamic vascular supply and nuclei involved.
(Bogousslavsky et al., 1991; Engelborghs et al., 2000; Habib, 2004)
Though descriptions of disorders of diminished motivation after da-
mage to the anterior territory of the thalamus seems to be rare, it is
known that anterior involvement is also associated with a variety of
behavioral changes. (Carrera and Bogousslavsky, 2006) In studies on
cats and monkeys, bilateral lesions of the anterior nucleus of the tha-
lamus have produced symptoms similar of an akinetic state.(Freemon,
1971; Meyer and Hunter, 1952) Moreover, Carota et al. described a
patient with AM after bilateral thalamo-polar artery stroke and damage
to the anterior nuclei of the thalamus.(Carota et al., 2014) While these
observations suggests that different thalamic nuclei are fundamental
relays associated with motivation and purposeful behavior, bilateral
lesions in both dorsomedial and anterior thalamic nuclei inflicted for
the treatment of psychiatric disorders have not produced AM, which
questions the role of these structures in the development the disease.
(Spiegel et al., 1953)
In essence, the feedforward parallel organization of the above-de-
scribed frontal-subcortical circuits creates the anatomical framework
for the integration and transformation of information from different
functional regions of the cerebral cortex.(Haber, 2016) Goal-directed
behavior is the end-result of complex information integration from
limbic, cognitive, and motor domains within this frontal-subcortical
system. All structures within this system (described in I, II, IIIa and IIIb)
need to work in concert with each other to process the complex chain of
events that produce goal-directed behavior. Removing a single element
of this frontal-subcortical orchestra can severely affect the drive for
actions, including emotions, motivation, and cognition. This explains
why damage to different parts of (pre)frontal and subcortical structures
has been demonstrated to lead to similar behavioral or cognitive defi-
cits, such as severe combined akinesia and mutism.
4. Treatment of akinetic mutism
The treatment of transient or chronic AM remains difficult and re-
ports in the literature on possible treatment strategies, optimal doses,
and duration of treatment are limited. It is obvious that the first step in
the treatment of AM remains the resolution of its underlying cause.
However, if AM represents a more permanent clinical state after severe
brain injury, a variety of drugs can be administered to diminish or re-
solve dysfunction of motivational neurocircuitry. Several drugs have
been reported in the literature to have an effect on patients with AM.
4.1. Dopamine agonist therapy
The first report on the use of DA agonists in AM was described by
Ross and Stewart.(Ross and Stewart, 1981) Increasing doses of Bro-
mocriptine, a DA agonist, were administered to a patient with AM after
revision surgery for a third ventricle tumor, resulting in a spectacular
improvement in both motor function and behavior. Ross and Stewart
hypothesized that bypassing the damaged ascending mesolimbic and
nigrostriatal dopaminergic pathways with direct DA agonists, acting at
the dopaminergic target areas, i.e., the striatum and or the (pre)frontal
cortex must have resulted in the direct improvement of akinesia and
mutism. Other authors have also extensively reported on the positive
effects of Bromocriptine in both AM and other motivational deficits
after brain injury since.(Anderson, 1992; Powell et al., 1996) Bromo-
criptine is a highly selective D2 DA receptor agonist. The highest levels
of D2 dopamine receptors are found in the striatum, the nucleus
accumbens, and the olfactory tubercle. D2 receptors are also expressed
at significant levels in the substantia nigra, VTA, and are present in both
the prefrontal and cingulate cortex, providing rich anatomical sub-
strates for drug-interactions in AM. It is thought that Bromocriptine
changes the regulation of inhibitory signalling through these D2-ex-
pressing receptors, improving activity in frontal regions through alter-
nation of top-down control of behavior and control of selective atten-
tion. However, it is most likely that Bromocriptine especially alters
complex frontal-subcortical signalling in the striatum through its high
D2 distribution there.(Beaulieu and Gainetdinov, 2011; Keeler et al.,
2014) Recently, Yang et al. demonstrated a specific reduction in striatal
dopaminergic uptake in a patient with acute AM and showed return to
normal levels at the 6-month follow-up with complete resolution of
clinical symptoms.(Yang et al., 2007) Since there is a characteristic
dose-dependency for Bromocriptine, it seems that a certain ‘threshold’
of D2 receptor occupancy must be reached to restore the associated
frontal lobe dysfunction and motivational deficits in AM. Some authors
have hypothesized that this dose-dependency can be explained by the
low ratio of D2 receptors in the prefrontal and anterior cingulate cortex
compared with D1 receptors.(Crismon et al., 1988; Hall et al., 1994) L-
dopa, a presynaptic DA agonist works on both D1 and D2 receptors of
(pre)frontal regions and the striatum and is also known to result in
neurological recovery in AM patients.(Combarros et al., 2000; Deborah
et al., 2017) However, dopaminergic treatment remains experimental.
At present, a clinically important use of dopaminergic agonists, such as
L-dopa, is countering behavioral deficits thought to be associated with
lowered levels of DA metabolites and concomitant frontal lobe dys-
function in patients with traumatic brain injury.(Chew and Zafonte,
2009; Diaz-Arrastia et al., 2014)
4.2. Treatment with methylphenidate and atomoxetine
In addition to DA agonists, AM has been treated with drugs that
alter both noradrenaline and DA levels in the brain, such as
Methylphenidate and Atomoxetine. In 1958, Daly and Love successfully
treated AM with Methylphenidate.(Daly and Love, 1958) Methylphe-
nidate is thought to increase the synaptic concentration of both DA and
noradrenaline by blocking the DA and noradrenaline transporter.(Leo-
nard et al., 2004) Methylphenidate specifically increases both pre-
frontal and striatal levels of DA and noradrenaline, which may account
for the re-activation of frontal (sub)cortical circuitry and restorative
effects of the drug in patients with disorders of diminished motivation
and initiation.(Berridge et al., 2006; Volkow et al., 2001) In 2010, Kim
and You described a case of a patient with AM after bilateral frontal
lobe injury that clinically responded to increasing doses of Atomox-
etine.(Kim et al., 2010) In contrast to Methylphenidate, Atomoxetine is
mainly associated with an increase in extracellular concentrations of
noradrenaline and DA in the prefrontal cortex and likely does not alter
DA levels in the striatum.(Bymaster et al., 2002) However, the re-ac-
tivation of prefrontal cortical areas may have a strong widespread effect
on connectivity and impact other parts of the frontal-subcortical system
involved in the regulation of dopaminergic neurotransmission.(Easton
et al., 2007; Taber et al., 1995) Furthermore, Atomoxetine has been
associated with improvements of cognitive functions and attentional
processes and has gained considerable attention from the clinical
community for treating frontal lobe symptoms after traumatic brain
injury.(Arnsten, 1998; Bymaster et al., 2002; Chew and Zafonte, 2009;
Diaz-Arrastia et al., 2014; Gamo et al., 2010; Watanabe et al., 1995)
4.3. ‘Awakenings’ after zolpidem
Zolpidem is a non-benzodiazepine short-acting allosteric agonist of
the a1 receptor subtype of the gamma aminobutyric acid receptor
complex (GABA) with well-established sleep-promoting properties.
(Gosseries et al., 2014) Zolpidem is known to produce a paradoxical
‘awakening’ effect in patients with AM, though its effects are short-
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lasting and patients show a significant ‘wearing-off’ phenomenon.
(Brefel-Courbon et al., 2007) Temporary neurological recovery after
Zolpidem has also been reported in a small and specific subset of other
patients with severe brain injury, especially in those with disorders of
consciousness.(Bomalaski et al., 2017; Clauss et al., 2000) It has been
suggested that the paradoxical effects of Zolpidem could be attributable
to the modulation of subcortical connectivity, particularly at the level
of the GP.(Schiff, 2010) According to Schiff et al., severe brain damage
to cortical and/or subcortical structures might cause the striatum to fail
to inhibit the inhibitory outflow of the GPi to the thalamocortical
system. This general loss of active inhibition from the striatum causes a
pathological ‘hyperactive’ GPi that, in turn, results in increased tha-
lamic inhibition and thereby disturbs anterior forebrain signalling.
These changes result in a reduction of spontaneous behavior or even
loss of consciousness. This ‘downstate’ might also be responsible for the
loss of initiation and motivation for behavior in AM. Zolpidem is
thought to have a direct disinhibiting influence on these pathological
GPi outflow signals, thereby re-activating the thalamocortical system
and restoring anterior forebrain signalling. A part of this hypothesis is
confirmed in several animal studies in which specific injections of
Zolpidem in the GP has been shown to lead to a decrease in firing rate
of GP neurons and changes in motor behavior of rats.(Chen et al., 2004;
Crone et al., 2017) In contrast, local application of a GABAa receptor
antagonist increased the firing rate of GP neurons.(Galvan et al., 2005)
Interestingly, Xue et al. found that application of a GABAa antagonist
induced stronger excitatory effects in the GP of rats with a previous
chemically induced lesion.(Xue et al., 2010) They suggested that this
phenomenon could be mediated by the expression of more postsynaptic
GABAa receptors or by the increased release of GABA from striato-
pallidal and/or pallido-pallidal terminals in an injured GP. This ob-
servation might be translated to patients with AM in which post-injury
subcortical upregulation of GABAa receptors and change of GABA re-
lease might be responsible for the paradoxical reaction to Zolpidem
administration. However, basal GABAergic control of (sub)cortical
structures, including the GP, might be more heterogeneous than what
was previously thought and Zolpidem’s actions in AM might be fol-
lowing a far more complex mechanism than proposed by Schiff et al.
(Brown and McKenna, 2015; Crone et al., 2017) After all, the model
seems insufficient to capture the whole pathophysiological spectrum of
AM, since it seems to disregard the relationship with focal GPi lesions
and AM (as described in IIIa), which would theoretically, and para-
doxically, result in GPi inactivity.
Another, more conceptual, hypothesis on Zolpidem action in pa-
tients with severe brain injury is that of 'neural dormancy' or 'diaschisis'.
(Demirtas-Tatlidede et al., 2013) It is thought that a neuroprotective
'dormancy' mechanism originates after severe brain injury, resulting in
a temporary rise in GABA levels to reduce and suppress brain activity
and excitotoxicity to facilitate the recovery of brain tissue and prevent
more neuronal loss. This neuroprotective GABA mechanism may still be
present in the chronic phase after brain injury, preventing the func-
tional activity of brain regions associated with initiation and motor
behavior. In this view, the paradoxical effect of Zolpidem could be
explained by a high specific GABAa action of vital, though dormant
'down-regulated' brain regions. A wide variety of structures maintain a
high density of GABAa a1 subunits, such as the substantia nigra, basal
forebrain, thalamic reticular nucleus, and lamina IV of sensorimotor
cortical regions, making them rich input and output structures for the
GABAergic effects of Zolpidem.(Dennis et al., 1988; Pinault, 2004) Fi-
nally, severe brain injury might also cause neural activity to lose its
power of complex information integration, resulting from hypersyn-
chronization among the neuronal population. It is thought that the
brain enters a state of pathological hypersynchronization after severe
brain injury, which is temporarily restored by GABA a1 sensitive de-
synchronization through Zolpidem.(Hall et al., 2010; Williams et al.,
2013)
5. Discussion
The function of the frontal lobes as an integrator of information
related both to the external sensory world and internal limbic system,
and its role in motivation and processing of motor reactions, makes this
region and its subcortical connections critically important in under-
standing the pathophysiology of AM.(Miller and Cummings, 2018)
There are several structures in the brain that are ‘usual suspects’ in the
development of AM, most prominently the ACC, but also the striatum,
GPi, and medial thalamus. Injury to any of these single structures seems
to be able to disrupt the processing and integration of information
within the frontal-subcortical circuit, resulting in AM. Since different
frontal-subcortical circuits integrate information from anatomically
disparate, but functionally related brain regions, a broad range of
structural lesions to different parts of the frontal-subcortical circuit
results in the development of a similar state of extreme sensory in-
attention. This corroborates the fact that AM has been described fol-
lowing a wide variety of lesions throughout the brain with a special role
for the ‘way stations’ in the above-described (pre)frontal basal-ganglia-
thalamocortical circuits. However, within this computational network,
it remains obscure what exact proportion each of these single structures
contribute to the general, broad AM condition. A synthesis of lesion
studies in animals, imaging studies in humans, and clinical investiga-
tions in patients with AM suggests that AM arises as a result of loss of an
‘energizing factor’ in the frontal-subcortical system. The (pre)frontal
cortex, in particular the ACC, may be considered the ‘battery’ that
contributes to motivational control, and facilitates neural processes
underlying behavior.(Holroyd and Yeung, 2012; Kouneiher et al., 2009)
Damage to the (pre)frontal cortex may result in the withdrawal of this
energizing factor following disconnection of frontal regions from their
associated striatal parts or following specific neurotransmitter defi-
ciencies, eventually resulting in the development of AM.(Habib, 2004;
Holroyd and Yeung, 2012, 2011) Loss of this ‘battery’ function might
also be the result of more distal injury or dysfunction of any of the
components of the nigrostriatal or mesolimbic pathways, impairing
dopaminergic input to frontal regions and the striatum. Subsequently,
the loss of neurotransmitter input to the striatum is thought to result in
disinhibition of the GPi neurons, which become tonically active, ex-
erting a powerful inhibiting influence on their thalamic targets.(Schiff,
2010) This negative influences frontal activity and forms a reinforcing
negative loop that impairs both spontaneous motor behavior and
speech, forming the basis of persisting AM. In addition to the well-
known role of cortico-basal ganglia circuits in the initiation and ex-
ecution of behavior, it is now thought that there are also specific cir-
cuits that are involved in proactive and reactive inhibition of behavior.
(Jahanshahi et al., 2015) Motivational processes emerge from a com-
petition process between these execution and inhibition systems that
act in parallel within the frontal-subcortical circuit.(Leblois et al., 2006;
Piron et al., 2016) Clinical manifestations of other basal ganglia-related
disorders, such as Parkinson’s disease, Tourette syndrome, and ob-
sessive-compulsive disorder are already thought to be related to im-
balances between these dual systems. Theoretically, AMmay also be the
result of a severe imbalance between these systems, and may be caused
by a damage-induced dominant over-inhibition of behavioral processes.
A variety of pharmacological interventions may be used in the
treatment of AM. Developing a rational pharmacologic approach to
akinetic mutism does not only depend upon knowledge of what brain
structures are affected, but also which neurotransmitter systems are
involved.(Ross and Stewart, 1981) Most reports have been written
about the effects of DA agonists, such as Bromocriptine, and Levodopa.
This treatment may be considered when there is specific damage to the
(pre)frontal cortex, damage to the midbrain or specific dysfunction of
the DA conveying pathways. However, the effects of DA agonists are
usually dose-dependent, subacute and only become evident after a
couple days of treatment. Therefore, it is justified to start with a short
trial of 10 mg Zolpidem, since a positive effect can be registered almost
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instantly, with the use of a single dose. If there is no effect, it is con-
ceivable to start a trial of Bromocriptine, Levodopa or drugs that affect
both dopaminergic and noradrenergic transmission, such as Methyl-
phenidate, or Atomoxetine. However, it is important to remember that
most studies in patients with AM were performed without formal be-
havioral assessments, blinding and medication free intervals, possibly
causing bias of treatment. Currently, a wide variety of other pharma-
cological interventions are studied to treat a diverse set of symptoms of
frontal lobe dysfunction associated with severe brain injury, such as
amantadine and cholinesterase inhibitors.(Chew and Zafonte, 2009;
Diaz-Arrastia et al., 2014) Most drugs are currently undergoing phase II
or phase III clinical evaluation for which results are pending, and their
specific effects in patients with AM remain unknown. Therefore,
treatment remains experimental, and not without any consequences.
Long-term treatment with DA agonist is fraught with significant po-
tential adverse effects, including disabling dyskinesia. Moreover, do-
paminergic and GABAergic drugs can induce significant side-effects in
AM patients and have to be carefully considered and selected.(Jeon
et al., 2017)
6. Conclusion
AM is a rare, but severe neurological disorder. Patients with AM
lack the motivating vector for the expression of spontaneous motor
behavior and speech. It results in near-complete dependence on others
for the most basic activities of daily life, invariably leading to nursing
home admission. AM seems to arise as a result of a severe imbalance in
the integration of information within the frontal-subcortical loop. The
disorder may arise after brain damage, through a lack of an ‘energizing
factor’ for expressing spontaneous behavior, or through damage-asso-
ciated over-inhibition of behavior. The numerous structures and the
many neurotransmitters, receptors, and modulators involved in this
frontal-subcortical system account for the observation that lesions in
different brain regions may have similar behavioral effects and that a
variety of medications may have similar effects on behavioral dis-
turbances. A series of pharmacological interventions, depending on
individual pathophysiology, may be administered to patients in order to
restore the imbalance in motivational neurocircuitry. Future studies,
with more patients, specific neuroimaging procedures, neuropsycholo-
gical evaluations, and placebo-controlled administration of drugs seem
necessary to clarify the frontal-subcortical dysfunction in this enigmatic
disease.
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